NHS fast-tracks access to Epidyolex for severe epilepsy
Doctors will be able to prescribe the drug from January 6
Read More
Tag: LGS
GW Pharma’s Epidiolex nears US launch
GW Pharmaceuticals and its subsidiary Greenwich Biosciences are gearing up to launch Epidiolex in the US after drug enforcement officials re-classified the cannabis-based medicine to the lowest restriction.
Read More
NEJM publishes second successful Epidiolex trial in LGS
The New England Journal of Medicine has published the second of two late stage studies showing that GW Pharma’s cannabinoid Epidiolex cut seizures in patients with the rare childhood epilepsy Lennox-Gastaut Syndrome.
Read More
FDA advisors back approval of GW’s Epidiolex
As expected, an FDA advisory panel has backed approval of GW Pharmaceuticals/Greenwich Bioscience’s Epidiolex for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
Read More
GW’s Epidiolex takes a leap toward US approval
Shares in GW Pharma were given a boost after its cannabinoid Epidiolex took a giant leap towards US approval for treating seizures linked with Lennox-Gastaut (LGS) and Dravet syndromes.
Read More
Lancet-published data show potential of GW’s Epidiolex
The Lancet has published data from a Phase III study backing use of GW Pharmaceutical/Greenwich Bioscience’s Epidiolex in patients with Lennox-Gastaut syndrome (LGS).
Read More
GW’s cannabinoid Epidiolex under EU, US review
Regulators on both sides of the Atlantic are now reviewing GW Pharmaceuticals’ cannabinoid Epidiolex as a potential treatment for seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome.
Read More
GW completes Epidiolex submission
GW Pharmaceuticals and its US subsidiary Greenwich Biosciences have completed the rolling submission of Epidiolex as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two difficult-to-treat forms of childhood-onset epilepsy.
Read More
GW’s Epidiolex on track for LGS filing mid-year
GW Pharma’s Epidiolex has impressed again in a late-stage trial involving patients with the rare form of epilepsy Lennox-Gastaut Syndrome (LGS), significantly reducing the number of drop seizures experienced.
Read More
Orphan status for GW’s rare epilepsy drug
London, UK-based GW Pharmaceuticals’ cannabinoid Epidiolex has been awarded Orphan status by European regulators as a treatment for Lennox-Gastaut Syndrome (LGS), a rare and severe form of childhood-onset epilepsy.
Read More
GW Pharma’s cannabinoid hits targets in epilepsy trial
GW Pharmaceuticals has unveiled yet more positive data from a late-stage programme testing its cannabinoid Epidiolex in rare epilepsies, pushing its stock up more than 16 percent.
Read More
GW Pharma’s Epidiolex hits targets in rare epilepsy trial
GW Pharmaceuticals’ cannabinoid Epidiolex continues to impress in late-stage clinical trials, with a Phase III study involving patients with Lennox-Gastaut syndrome – a rare and severe form of childhood-onset epilepsy – the latest to hit its targets.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
